Gold prices steady ahead of Fed decision; weekly weakness noted
LONDON - Ameriprise Financial Inc (NYSE:AMP)., the Minneapolis-based financial services giant, has decreased its holdings in UK-based gene and cell therapy company Oxford Biomedica PLC, according to a regulatory filing. The notification, filed on February 18, 2025, and completed in Swindon, UK, revealed that Ameriprise’s voting rights in Oxford Biomedica fell below the previous threshold on February 14, 2025.
The total voting rights now held by Ameriprise Financial in Oxford Biomedica amount to approximately 3.886%, a decrease from the previously reported 5.099%. This change is a result of adjustments in both direct and indirect voting rights associated with shares and financial instruments, respectively. Specifically, Ameriprise now holds 4,108,146 direct voting rights, which equates to 3.877% of Oxford Biomedica’s voting rights. Additionally, financial instruments, namely stock on loan, account for 9,599 voting rights or 0.009%.
The filing detailed the chain of control through which the voting rights and financial instruments are held, listing several entities under Ameriprise Financial’s umbrella. These include Columbia Threadneedle Investments UK International Limited and Threadneedle Asset Management Limited, among others, all ultimately controlled by Ameriprise Financial, Inc.
Oxford Biomedica is known for its work in the development and manufacturing of gene and cell-based medicines. The company’s shares are traded on the London Stock Exchange (LON:LSEG) with the ticker symbol LSE:OXB. The information disclosed in the filing is based on standard regulatory requirements for major holdings notifications in the UK.
This adjustment in Ameriprise Financial’s stake in Oxford Biomedica is part of the standard ebb and flow of institutional investment in publicly traded companies. It is important to note that such changes in shareholding can influence investor sentiment and market dynamics. However, the filing does not indicate the reasons behind Ameriprise Financial’s decision to reduce its stake.
Investors and market watchers often monitor these filings to understand the movements of major institutional investors and their potential impact on the companies they invest in. The disclosure is based on a press release statement and provides transparency in the market, allowing stakeholders to stay informed about significant changes in company ownership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.